Nucleoside derivatives for treating hepatitis C virus infection

Details Nucleoside derivatives for treating hepatitis C virus infection Nucleoside derivatives for treating hepatitis C virus infection

2006-08-22

2006-08-22

Jiang, S. Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S026230, C536S026260, C536S026700, C536S027200

Reexamination Certificate

active

07094768

ABSTRACT:
Disclosed are 6-hydroxyamino- or a 6-alkoxyamino-7-deazapurine-ribofuranose derivatives, salts, pharmaceutical compositions, and methods of use thereof for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.

REFERENCES:
patent: 5681941 (1997-10-01), Cook et al.
patent: 5763167 (1998-06-01), Conrad
patent: 5977332 (1999-11-01), Martin
patent: 6475985 (2002-11-01), Wagner et al.
patent: 2003/0130226 (2003-07-01), Loakes et al.
patent: WO/1994/18215 (1994-08-01), None
patent: WO/1995/07919 (1995-03-01), None
patent: WO/2003/061576 (2003-07-01), None
patent: WO2003/061576 (2003-07-01), None
patent: WO 03/07257 (2003-09-01), None
patent: WO/2004/028481 (2004-04-01), None
patent: WO/2004/065398 (2004-08-01), None
Beigelman et al. “New Syntheses of 2′-C-Methylnucleosides Starting from D-Glucose and D-Ribose”Carbo. Research, 166:219-232 (1987).

Affiliated with

Also associated with

Rating

Nucleoside derivatives for treating hepatitis C virus infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleoside derivatives for treating hepatitis C virus infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside derivatives for treating hepatitis C virus infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3695740